1. Home
  2. AVAV vs GMAB Comparison

AVAV vs GMAB Comparison

Compare AVAV & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVAV
  • GMAB
  • Stock Information
  • Founded
  • AVAV 1971
  • GMAB 1999
  • Country
  • AVAV United States
  • GMAB Denmark
  • Employees
  • AVAV N/A
  • GMAB N/A
  • Industry
  • AVAV Aerospace
  • GMAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • AVAV Industrials
  • GMAB Health Care
  • Exchange
  • AVAV Nasdaq
  • GMAB Nasdaq
  • Market Cap
  • AVAV 18.9B
  • GMAB 17.4B
  • IPO Year
  • AVAV 2007
  • GMAB N/A
  • Fundamental
  • Price
  • AVAV $380.65
  • GMAB $28.95
  • Analyst Decision
  • AVAV Strong Buy
  • GMAB Strong Buy
  • Analyst Count
  • AVAV 13
  • GMAB 7
  • Target Price
  • AVAV $349.23
  • GMAB $41.17
  • AVG Volume (30 Days)
  • AVAV 1.2M
  • GMAB 2.7M
  • Earning Date
  • AVAV 12-03-2025
  • GMAB 11-06-2025
  • Dividend Yield
  • AVAV N/A
  • GMAB N/A
  • EPS Growth
  • AVAV N/A
  • GMAB 77.72
  • EPS
  • AVAV N/A
  • GMAB 21.62
  • Revenue
  • AVAV $1,085,820,000.00
  • GMAB $3,646,881,232.00
  • Revenue This Year
  • AVAV $148.47
  • GMAB $24.25
  • Revenue Next Year
  • AVAV $16.92
  • GMAB $16.29
  • P/E Ratio
  • AVAV N/A
  • GMAB $13.03
  • Revenue Growth
  • AVAV 44.03
  • GMAB 32.97
  • 52 Week Low
  • AVAV $102.25
  • GMAB $17.24
  • 52 Week High
  • AVAV $417.86
  • GMAB $33.65
  • Technical
  • Relative Strength Index (RSI)
  • AVAV 59.86
  • GMAB 40.26
  • Support Level
  • AVAV $345.28
  • GMAB $29.57
  • Resistance Level
  • AVAV $391.16
  • GMAB $30.24
  • Average True Range (ATR)
  • AVAV 19.39
  • GMAB 0.70
  • MACD
  • AVAV -4.53
  • GMAB -0.61
  • Stochastic Oscillator
  • AVAV 53.69
  • GMAB 6.00

About AVAV AeroVironment Inc.

AeroVironment Inc supplies unmanned aircraft systems, tactical missile systems, high-altitude pseudo-satellites, and other related services to government agencies within the United States Department of Defense as well as the United States allied international governments. The systems can help with security, surveillance, or sensing, and provide eyes in the sky without needing an actual person, or driver in the sky. The company is a defense technology provider delivering integrated capabilities across air, land, sea, space, and cyber. It develops and deploy autonomous systems, precision strike systems, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities. Company operates in three segments: UxS, LMS, MW.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: